Drupal.behaviors.print = function(context) {window.print();window.close();}>
Phosphoproteomics Study Drives Phase I Trial Testing Pfizer ALK Inhibitor as Breast Cancer Therapy
November 18, 2011
Phosphoproteomics Study Drives Phase I Trial Testing Pfizer ALK Inhibitor as Breast Cancer Therapy
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Theranostics Health to Launch Breast Cancer Dx in Early 2013, Raise $5M to $10M in Funding
June 15, 2012 / ProteoMonitor
Theranostics Health to Launch HER Signaling Assay, Marking Firm's First Commercial Test Release
May 3, 2013 / ProteoMonitor
MD Anderson RPPA Study Reveals New Potential Drug Targets in Small Cell Lung Cancer
September 14, 2012 / ProteoMonitor
Case Study Suggests FISH Test May Miss Some Patients Who Could Benefit from Crizotinib
September 12, 2012 / Pharmacogenomics Reporter
Mayo Study Finds Expanded Protein Panel Fails to Predict Outcome of Herceptin Treatment
December 16, 2011 / ProteoMonitor